Predicting efficacy and toxicity of drug combinations in salivary gland cancers: A model based on phase II trials.
BACKGROUND: Salivary gland cancers (SGCs) are rare and heterogeneous tumors lacking standard systemic treatment options in the recurrent/metastatic setting. Although clinical trials have shown activity of anti-HER2, chemotherapy, androgen receptor-targeted agents (ARTA) and androgen deprivation therapies (ADT), their combined effects remain largely unexplored. We aimed to model the potential outcomes of rational drug combinations to guide future clinical trial designs. METHODS: Fifteen phase II trials were included, encompassing 524 patients (19% female, 81% R/M, 55% ductal, 11% adenocarcinoma, 5% mucoepidermoid). 7 trials assessed cytotoxic chemotherapy, 6 ARTA ± ADT, and 5 anti-HER2 therapies (3 as antibody-drug conjugates, ADCs). Overall response rate (ORR) and grade ≥ 3 treatment-related adverse events (TRAEs) were estimated using Bliss and additivity models. Median progression-free survival and overall survival (OS) were reconstructed using parametric survival models. RESULTS: Sixty combinations were assessed. In AR + HER2 + disease, triple combinations involving ARTA-ADT and anti-HER2-ADCs, or chemotherapy plus anti-HER2 yielded the highest predicted ORRs (94.5% by Bliss). In AR + HER2-, chemotherapy-based combinations and ARTA-ADT showed a greater relative ORR gain overall compared with AR + HER2+: +14.29(1.1-21.9) vs + 6.26(0.8-14.3). Estimated median 5- and 3-year OS was achieved in AR + HER2 + and AR + HER2- combinations respectively. Grade ≥ 3 TRAEs showed the highest rates in chemotherapy regimens (93.1 by Bliss, uncapped 126.5% by additivity) and lower toxicity with ADCs (23.3%, 24.8%). CONCLUSIONS: Predicted efficacy and safety outcomes highlight potential rational drug combinations that merit evaluation in future SGC clinical trials, ideally using a sequential approach, with particularly promising incremental benefit in AR + HER2- disease. Expected toxicity may constrain the feasibility of certain combination strategies.
Authors
- Glenn J. Hanna (ORCID: https://orcid.org/0000-0002-9969-2523)
- Judit Sanz-Beltran (ORCID: https://orcid.org/0000-0001-7526-4973)
- Santiago Cabezas-Camarero (ORCID: https://orcid.org/0000-0003-4756-7031)
- Pablo Jiménez-Labaig (ORCID: https://orcid.org/0000-0002-7695-675X)
- Martin David Forster (ORCID: https://orcid.org/0000-0003-3876-7269)
- Irene García
- Robert Metcalf
- Kevin J. Harrington
- Paolo Bossi
Institutions
- Universitat Autònoma de Barcelona (ES)
- Royal Marsden NHS Foundation Trust (GB)
- Humanitas University (IT)
- University College London Hospitals NHS Foundation Trust (GB)
- Institute of Cancer Research (GB)
- Hospital de Sant Pau (ES)
- University of Manchester (GB)
- Hospital Clínico San Carlos (ES)
- Dana-Farber Cancer Institute (US)
- Royal Marsden Hospital (GB)
- Vall d'Hebron Hospital Universitari (ES)
- The Christie Hospital (GB)
- The Christie NHS Foundation Trust (GB)
- IRCCS Humanitas Research Hospital (IT)
- Vall d'Hebron Institute of Oncology (ES)
Publication Details
- Journal
- PubMed
- Published
- 2026-11-13
- DOI
- https://doi.org/10.1016/j.oraloncology.2026.108228
- Primary Topic
- Salivary Gland Tumors Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00